CXCR4 with gp120, can cause upregulation of TRAIL receptors and consequent sensitivity to apoptosis by this pathway. In this work, our aim was to measure if CD4+T lymphocytes from HIV+ patients, had and increased expression of TRAIL ligand and death receptors (DR) 5/4 and coreceptor CXCR4 and, evaluate its association

Methods Ten HIV+ ART naïve patients and seven HIV-donors were recruited. The immunophenotyping of CD4+T lymphocytes was performed with CD3+/CD4+ labeling, after that the TRAIL death receptors DR4 and DR5 as well as the TRAIL ligand and the coreceptor CXCR4 were measured for expression and MFI (median fluorescence intensity) by flow cytometry in whole blood samples

Results CD4+T lymphocytes from HIV+ patients showed an augmented expression and MFI of both death receptors and TRAIL ligand compared with the healthy controls; on the other hand, expression of coreceptor CXCR4 was increased in the HIV+ group and the MFI showed a significant difference compared to healthy subjects. Correlations between DR4 and the TRAIL ligand with CXCR4 showed no significance; in contrast, both expression and MFI of DR5 and CXCR5 were significant and showed a strong direct correlation (expression: $p < 0.05$ $r = 0.69$ and MFI: $p < 0.005$ $r = 0.81$).

Conclusion There is evidence of apoptosis triggered by CXCR4 activation, not related to the Fas pathway, which is one of the main causes related to cell depletion in HIV infection. The upregulation of the TRAIL pathway in HIV infected subjects is correlated with the CXCR4 expression, which could be the cause of the reported apoptosis in these patients.

Disclosure No significant relationships.

P170

EFAVIRENZ BASED ANTI-RETROVIRAL REGIMENS IN PAEDIATRICS: A PEEP INTO NEUROPSYCHIATRIC AND BIOCHEMICAL DERANGEMENTS

¹Purba Chakrabarty*, ²Manasi Banerjee, ²Manab Nandy, ³Kalpna Datta, ⁴Rudraprasad Acharya, ⁵Arup Chakraborty, ⁶Pragnadyuti Mandal, ⁶Dipak Sarkar, ⁷Shatavisa Mukherjee, ⁸Mitali Basu, ⁹Ananya Bhowmik. ¹Medical College and Hospital, Kolkata, 88, College Street, Kolkata – 700073, West Bengal, India, Pharmacology, Dist – Bankura, West Bengal, India; ²Medical College and Hospital, Kolkata, Pharmacology, Kolkata, India; ³Medical College, Kolkata, Paediatrics, Nodal Officer and Programme Director, Paediatric Centre of Excellence in HIV Care, Regional Art Centre, Medical College and Hospital, Kolkata, India; ⁴Medical College and Hospital, Kolkata, Psychiatry, Kolkata, India; ⁵Medical College and Hospital, Kolkata, Community Medicine, Kolkata, India; ⁶Medical College, Kolkata, Pharmacology, Kolkata, India; ⁷School of Tropical Medicine, Kolkata, Patient Safety-pharmacovigilance, ADR Monitoring Centre, Kolkata, India; ⁸Bankura Sammilani Medical College and Hospital, Medicine, Nodal Officer, Fiart Centre, Bankura, India; ⁹Medical College and Hospital, Kolkata, Research Officer, Paediatric Centre Of Excellence in HIV Care, Regional Art Centre, Kolkata, India

10.1136/sextrans-2019-sti.329

Background Combination antiretroviral therapy (ART) has transformed HIV-AIDS into a chronically manageable illness. Efavirenz is an important component for ART regimens. Quality of life should be maintained for the easy continuation of this life-long therapy. Hence the adverse drug reaction (ADR) monitoring has become an important event to achieve good adherence

Objective This study aims to assess the spectrum of clinico-biochemical and neuropsychiatric ADRs for Efavirenz based ART in paediatric HIV patients

Methods Paediatric HIV-1 patients initiated with Efavirenz based ART were followed up for biochemical changes (liver, renal, lipid, haemoglobin parameters) and neuropsychiatric

adverse reactions (NPARs) till 6 months. NPAR(s) were monitored using Developmental Psychopathology Checklist and Sleep Disturbances Scale for Children. Adherence and guardian's literacy status were analyzed for their association with the self-reporting of NPAR(s).

Results NPARs were observed to be maximum at 15th day, followed by a gradual decrease over 1st and 2nd month. Symptoms like learning disorder and psychosis were maximum, followed by hyperkinesia, emotional disorder and somatisation. Domains of sleep problems were maximum at 15th day, followed by a graded decrease in the 1st and 2nd month. Self-reporting was found to be 57.14% and 37.50% in guardian with secondary and primary education respectively. Decreased adherence was noted among 16.67% of patients, managed by proper counseling. While biochemical changes like liver function alterations were observed to be maximum at 6th month (30.39%) and 4th month (7.84%), changes in renal function and lipid parameters were observed to be maximum at 6th month and drop in haemoglobin at 3rd month.

Conclusion Sensitization about NPAR(s) should be ensured at the time of therapy initiation to warrant adherence and spontaneous reporting in order to prevent resistance and treatment failure. ART induced anaemia, altered lipid profile, liver and kidney function derangements could be life threatening. This study thus upsurges the need for focused pharmacovigilance and therapeutic drug monitoring of ART for safer patient outcomes.

Disclosure No significant relationships.

P171

ZBTBS GENE EXPRESSION IN CD4+ T CELLS AND SYSTEMIC PRO-INFLAMMATORY CYTOKINES IN NAÏVE AND TREATED HIV PATIENTS

¹Judith De Arcos Jimenez*, ¹Mariana Ruiz Briseño, ¹Moises Ramos Solano, ²Jaime Andrade-Villanueva, ¹Luz Gonzalez-Hernandez, ¹Karina Sanchez-Reyes. ¹Universidad de Guadalajara, Guadalajara, Mexico; ²Hospital Civil Fray Antonio Alcalde, Unidad De VIH, Guadalajara, Mexico

10.1136/sextrans-2019-sti.330

Background Chronic inflammation in HIV infection has been associated with accelerated disease progression. Several external host factors contribute to inflammation like, microbial translocation and coinfections; as well as host intrinsic mechanisms; such as immune activation and the regulation of factors that participate in inflammation pathways. Members of the transcriptional factors ZBTB have been associated with repression of proinflammatory cytokines; the objective of this work was to identify if ZBTB repressors could be contributing to cytokines levels decrease in HIV+ ART-treated patients.

Methods CD4+ T cells were isolated from 12 HIV- and 21 HIV+, subclassified as naïve (n= 8) and treated (undetectable for ≥ 1 year, n=13). Gene expression of ZBTB2, ZBTB4, ZBTB7B, ZBTB17, ZBTB38, BCL6 and ZNF131 was determined by qRT-PCR. Cytokine levels were quantified (IL-1 β , IFN- α , IFN- γ , TNF- α , MCP-1, IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IL-23, IL-33) by flow cytometry in serum. Kruskal-Wallis test was used for statistical analysis.

Results In naïve patients, only ZBTB7B showed a significant up-regulation (2.76 fold). BCL6, ZBTB4, ZBTB38 had an increase but, were not significant (1.01, 0.91, 0.13 fold respectively); treated patients showed a significant up-regulation in ZBTB7B, ZBTB4 and ZBTB38 (2.23, 1.13, 1.04 fold respectively) and, BCL6 had 1.02 fold, however, it was no